{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":4,"x_thread":4,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03706690\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PACIFIC-5","nct_id":"NCT03706690","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific-5-nct03706690. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"PACIFIC-5","arms":[{"description":"Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks \\[q4w\\] intravenously \\[iv\\] until clinical progression/deterioration or confirmed radiological progression)","label":"Durvalumab Therapy","type":"EXPERIMENTAL"},{"description":"Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)","label":"Placebo Therapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":407,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-08-06","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)","timeFrame":"Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)"}],"references":[{"citation":"Wu YL, Wu L, Bi N, Cil T, Ge H, Zhu Z, Wang CL, Zhang W, Lv D, Mingyan E, Sun J, Pan Y, Krzakowski M, Dikilitas M, Sendur MAN, Kim YC, Yang Y, Mao R, Zhang B, Wang L. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. J Hematol Oncol. 2025 Dec 7;18(1):111. doi: 10.1186/s13045-025-01768-1.","pmid":"41354932","type":"DERIVED"}],"start_date":{"date":"2018-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03706690"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific-5-nct03706690"}